SITE004-0194

SITE004 (DEU) › SITE004-0194

SITE004-0194

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE004 (DEU) · Dr. Tanaka
consented 2026-04-21

enrolled

AEs

3

Serious

1

Dropout signal

–

Adverse events

3

Grade 2 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2023-03-15 (study day 134); relationship: not assessed

moderate assessed

Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2022-11-08 (study day 7); relationship: RELATED

moderate assessed

Grade 3 Fatigue — outcome: RECOVERED/RESOLVED; onset 2022-11-04 (study day 3); relationship: not assessed; serious criteria: hospitalization

severe serious assessed

Data queries

0

No data queries. Open queries would appear here for this patient.